{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:45:52Z","timestamp":1793508352593,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11523-017-0525-2","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T06:39:51Z","timestamp":1502347191000},"page":"655-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers"],"prefix":"10.1007","volume":"12","author":[{"given":"Bernard","family":"Escudier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Germann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Fartoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hal","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"525_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-013-2321-8","volume":"73","author":"E Raymond","year":"2014","unstructured":"Raymond E, Dalgleish A, Damber JE, et al. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014;73:1\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"525_CR2","doi-asserted-by":"crossref","first-page":"e34207","DOI":"10.1371\/journal.pone.0034207","volume":"7","author":"E K\u00e4llberg","year":"2012","unstructured":"K\u00e4llberg E, Vogl T, Liberg D, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One. 2012;7:e34207.","journal-title":"PLoS One"},{"key":"525_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-015-0098-5","volume":"3","author":"A Olsson","year":"2015","unstructured":"Olsson A, Nakhl\u00e9 J, Sundstedt A, et al. Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. J Immunother Cancer. 2015;3:53.","journal-title":"J Immunother Cancer"},{"key":"525_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2326-6066.CIR-14-0036","volume":"3","author":"L Shen","year":"2015","unstructured":"Shen L, Sundstedt A, Ciesielski M, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res. 2015;3:136\u201348.","journal-title":"Cancer Immunol Res"},{"key":"525_CR5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618\u201331.","journal-title":"Nat Rev Cancer"},{"key":"525_CR6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","volume":"8","author":"G Bergers","year":"2008","unstructured":"Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer. 2008;8:592\u2013603.","journal-title":"Nat Rev Cancer"},{"key":"525_CR7","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","volume":"29","author":"R Pili","year":"2011","unstructured":"Pili R, H\u00e4ggman M, Stadler WM, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022\u20138.","journal-title":"J Clin Oncol"},{"key":"525_CR8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","volume":"34","author":"C Sternberg","year":"2016","unstructured":"Sternberg C, Armstrong A, Pili R, et al. Phase III, randomized, double-blind, placebo-controlled study of tasquinimod in men with metastatic castrate-resistant prostate cancer. J Clin Oncol. 2016;34:2636\u201343.","journal-title":"J Clin Oncol"},{"key":"525_CR9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"525_CR10","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1002\/sim.2866","volume":"26","author":"S Litwin","year":"2007","unstructured":"Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Stat Med. 2007;26:4400\u201315.","journal-title":"Stat Med"},{"key":"525_CR11","doi-asserted-by":"crossref","unstructured":"Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014;26:521\u20138.","DOI":"10.1097\/CCO.0000000000000110"},{"key":"525_CR12","doi-asserted-by":"crossref","unstructured":"Fizazi K, Ulys A, Sengel\u00f8v L et al (2017). A randomized, double blind, placebo controlled phase 2 study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Annals Oncol (in press)","DOI":"10.1093\/annonc\/mdx487"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-017-0525-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T06:44:14Z","timestamp":1569998654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-017-0525-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s11523-017-0525-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}